What is Milestone Pharmaceuticals's market cap?

Milestone Pharmaceuticals (MIST) has a market capitalization of $163.1M and trades on NASDAQ.

Who are Milestone Pharmaceuticals's competitors?

Milestone Pharmaceuticals's key competitors include Sanofi, Pfizer, Medtronic plc, and others. These companies compete in similar markets and product categories.

Who does Milestone Pharmaceuticals partner with?

Milestone Pharmaceuticals's notable partners include Corxel, Apple.

Where is Milestone Pharmaceuticals headquartered?

Milestone Pharmaceuticals is headquartered in Canada and employs approximately 47 people. It has been publicly traded since 2019.

Milestone Pharmaceuticals

MIST

Milestone Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular medicines.

Market cap

$163.09M-25.0%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$238.0KMiss by $29.9M EPS-$0.20Miss by $0.26

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$1.1M

EPS estimate-$0.18

Competitors

By market cap

Pfizer$138.21B-3.7%

Medtronic$105.46B-6.1%

Boston Scientific$66.9B-56.5%

Tenet Healthcare$17.8B+10.8%

Mineralys Therapeutics, Inc.$2.6B+190%

AMP

Amphastar Pharmaceuticals$838.6M-22.2%

Inhibikase Therapeutics, Inc.$269.3M+87.7%

Milestone Pharmaceuticals$163.1M+40.6%

By revenue growth

Boston Scientific+17.4%

Medtronic+8.4%

Tenet Healthcare+4.5%

Pfizer+1.4%

AMP

Amphastar Pharmaceuticals-1.4%

By net margin

Boston Scientific17.26%+5.7pp

Pfizer15.65%+6.3pp

Medtronic13.2%-0.7pp

Tenet Healthcare12.36%+0.9pp

AMP

Amphastar Pharmaceuticals11.0%-8.4pp

Profile

Milestone Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular medicines. Its primary focus is on patient-administered, rapid-onset treatments for episodic heart conditions, utilizing a proprietary medicinal chemistry approach to create fast-acting calcium channel blockers. The company's lead product is the first FDA-approved self-administered nasal spray designed to terminate acute cardiac episodes outside of a clinical setting.

Competitive position

Milestone holds a first-mover advantage with the only FDA-approved self-administered treatment for PSVT, positioned as a disruptive alternative to emergency department visits and invasive procedures.

GeographiesUnited States, European Union, China

Customer segmentsPatients, Healthcare Providers, Payors

Business modelDrug Developer, Product Commercialization, Licensing and Royalties

SuppliersActive pharmaceutical ingredient (API) manufacturers, Nasal spray device manufacturers, Contract formulation and assembly services, Packaging providers

CustomersThird-party logistics providers, Pharmaceutical wholesalers, Retail pharmacies, Patients with PSVT and AFib-RVR

CountryCanada

Listed2019

Employees47.0

CEOJoseph G. Oliveto

SectorHealthcare

IndustryBiotechnology

Websitemilestonepharma.com

FilingsSEC EDGAR

Questions, answered.

What is Milestone Pharmaceuticals's market cap?: Milestone Pharmaceuticals (MIST) has a market capitalization of $163.1M and trades on NASDAQ.
Who are Milestone Pharmaceuticals's competitors?: Milestone Pharmaceuticals's key competitors include Sanofi, Pfizer, Medtronic plc, and others. These companies compete in similar markets and product categories.
Who does Milestone Pharmaceuticals partner with?: Milestone Pharmaceuticals's notable partners include Corxel, Apple.
Where is Milestone Pharmaceuticals headquartered?: Milestone Pharmaceuticals is headquartered in Canada and employs approximately 47 people. It has been publicly traded since 2019.